Epic Deterioration Index May Identify High- and Low-Risk COVID-19 Patients
The Epic Deterioration Index (EDI) can identify subsets of high- and low-risk patients with coronavirus disease 2019 (COVID-19).
The Epic Deterioration Index (EDI) can identify subsets of high- and low-risk patients with coronavirus disease 2019 (COVID-19).
Mortality is higher in younger patients with COVID-19 compared with younger patients with influenza.
There appears to be a low risk of invasive fungal secondary infection, especially aspergillosis, in patients with SARS-CoV-2-related pneumonia and no underlying immunosuppression.
Duration-dependent beneficial effects of metformin, sulfonylurea, and thiazolidinedione use on COPD exacerbation have been observed in patients with COPD and diabetes.
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate may reduce the risk of death compared with glycopyrrolate/formoterol fumarate in patients with COPD.
A high rate of mortality from COVID-19 was seen in patients with preexisting fibrotic idiopathic interstitial lung disease (ILD) compared with patients with other ILDs.
Vitamin D deficiency is associated with a higher risk of incident nontuberculous mycobacteria respiratory isolation in adults with cystic fibrosis.
Close monitoring of patients with systemic sclerosis-associated interstitial lung disease and awareness of the variable course of progression is highly important in considering when to initiate treatment.
The accuracy of an integrated classifier in patients with indeterminate pulmonary nodules with a pretest probability for malignancy of at least 0% was confirmed.
The effects of positive end expiratory pressure in COVID-19-related acute respiratory distress syndrome (ARDS) are similar to those reported in classical ARDS.